"At ID Care Infectious Disease Hillsborough, we are part of the largest network of board-certified infectious disease specialists on the East coast and partners to leading healthcare organizations throughout NJ. Our experts are dedicated to the prevention, diagnosis and treatment of infectious diseases, from C. diff, pneumonia, hepatitis and HIV, through to STDs, tick and mosquito-borne diseases, UTIs, and more. Our physicians also specialize in care for infected wounds, infusion therapy, and protection from travel-borne illnesses, including vaccinations. For more information on our services or to make an appointment, contact ID Care Infectious Disease Hillsborough office at 105 Raider Boulevard, Suite 101 Hillsborough, NJ 08844."

During the past decade, I.D. Care, Inc. conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "I.D. Care, Inc." #1 sponsor was "Gilead Sciences" with 5 trials, followed by "Bristol-Myers Squibb" with 4 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 4 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Janssen Sciences Ireland UC" with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "I.D. Care, Inc." #1 collaborator was "Chiron Corporation" with 1 trials as a collaborator and "Community Programs for Clinical Research on AIDS" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "I.D. Care, Inc." are "HIV Infections" (13 trials), "Hepatitis B, Chronic" (2 trials), "Hepatitis C, Chronic" (2 trials), "COVID-19 Prevention" (1 trials) and "Chronic Hepatitis B" (1 trials). Many other conditions were trialed in "I.D. Care, Inc." in a lesser frequency.

Most popular intervention types in "I.D. Care, Inc." are "Drug" (18 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Didanosine" (3 trials), "JNJ-73763989" (3 trials), "Nelfinavir mesylate" (3 trials) and "Stavudine" (3 trials). Other intervention names were less common.

The vast majority of trials in "I.D. Care, Inc." are 24 trials for "All" genders.

Currently, there are NaN active trials in "I.D. Care, Inc.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in I.D. Care, Inc., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in I.D. Care, Inc., 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".